Table 5

Multivariate analyses of cytogenetic risk groups after unrelated donor transplantation for AML in second complete remission

OutcomeNo.Relative risk (95% CI)P
Treatment-related mortality*    
    Favorable 94 1.00‖ Poverall2 = .57 
    Intermediate 163 0.95 (0.65-1.38) .77 
    Unfavorable 36 0.70 (0.36-1.36) .29 
Relapse†    
    Favorable 94 1.00‖ Poverall2 = .11 
    Intermediate 163 1.54 (0.76-3.09) .23 
    Unfavorable 36 2.48 (1.06-5.80) .037 
Treatment failure‡    
    Favorable 94 1.00‖ Poverall2 = .66 
    Intermediate 163 1.16 (0.84-1.61) .37 
    Unfavorable 36 1.15 (0.70-1.90) .57 
Death§    
    Favorable 95 1.00‖ Poverall2 = .81 
    Intermediate 163 1.12 (0.80-1.56) .52 
    Unfavorable 36 1.10 (0.66-1.81) .72 
OutcomeNo.Relative risk (95% CI)P
Treatment-related mortality*    
    Favorable 94 1.00‖ Poverall2 = .57 
    Intermediate 163 0.95 (0.65-1.38) .77 
    Unfavorable 36 0.70 (0.36-1.36) .29 
Relapse†    
    Favorable 94 1.00‖ Poverall2 = .11 
    Intermediate 163 1.54 (0.76-3.09) .23 
    Unfavorable 36 2.48 (1.06-5.80) .037 
Treatment failure‡    
    Favorable 94 1.00‖ Poverall2 = .66 
    Intermediate 163 1.16 (0.84-1.61) .37 
    Unfavorable 36 1.15 (0.70-1.90) .57 
Death§    
    Favorable 95 1.00‖ Poverall2 = .81 
    Intermediate 163 1.12 (0.80-1.56) .52 
    Unfavorable 36 1.10 (0.66-1.81) .72 

CI indicates confidence interval.

*

Unfavorable vs intermediate: RR = 0.74, 95% CI = 0.39-1.40, P = .74. Other significant covariates were age at transplantation (Poverall2 = 0.002; 19-35 years vs ≤ 18 years: RR = 1.86, 95% CI = 1.17-2.95, P = .009; > 35 years vs ≤ 18 years: RR = 2.26, 95% CI = 1.43-3.59, P < .001; > 35 years vs 19-35 years: RR = 1.22, 95% CI = 0.82-1.81, P = .33), recipient CMV status (positive vs negative: RR = 1.53, 95% CI, 1.07-2.18, P = .020); conditioning regimen (Poverall2 = 0.034; Bu + Cy ± other vs CyTBI ± other: RR = 0.71, 95% CI = 0.41-1.23, P = .23; other vs CyTBI ± other: RR = 1.97, 95% CI = 1.07-3.63, P = .030; other vs BuCy ± other: RR = 2.76, 95% CI = 1.27-6.02, P = .011) and donor-recipient HLA match (mismatch vs match: RR = 1.53, 95% CI = 1.05-2.22, P = .027).

†

Unfavorable vs intermediate: RR = 1.61, 95% CI = 0.80-3.25, P = .18. Other significant covariate was duration of first CR (time-dependent covariate). The effect of duration of first CR differs with the length of time after transplantation (> 12 months vs ≤ 12 months within first 6 months after transplantation: RR = 0.08, 95% CI = 0.01-0.62, P = .15; > 12 months vs ≤ 12 months beyond first 6 months after transplantation: RR = 1.86, 95% CI = 0.86-4.00, P = .11).

‡

Unfavorable vs intermediate: RR = 0.99, 95% CI = 0.62-1.58, P = .98. Other significant covariates were age at transplantation (Poverall2 = 0.017; 19-35 years vs ≤ 18 years: RR = 1.40, 95% CI = 0.97-2.03, P = .07; > 35 years vs ≤ 18 years: RR = 1.70, 95% CI = 1.18-2.45, P = .005; > 35 years vs 19-35 years: RR = 1.21, 95% CI = 0.85-1.71, P = .29) and conditioning regimen (Poverall2 = 0.017; Bu + Cy ± other vs CyTBI ± other: RR = 0.68, 95% CI = 0.43-1.06, P = .09; other vs CyTBI ± other: RR = 1.82, 95% CI = 1.04-3.18, P = .036; other vs BuCy ± other: RR = 2.69, 95% CI = 1.36-5.32, P = .004).

§

Unfavorable vs intermediate: RR = 0.89, 95% CI = 0.64-1.25, P = .94. Other significant covariates were age at transplantation (Poverall2 = 0.005; 19-35 years vs ≤ 18 years: RR = 1.58, 95% CI = 1.08-2.29, P = .017; > 35 years vs ≤ 18 years: RR = 1.83, 95% CI = 1.26-2.67, P = .001; > 35 years vs 19-35 years: RR = 1.16, 95% CI = 0.82-1.65, P = .39) and donor-recipient HLA match (mismatch vs match: RR = 1.40, 95% CI = 1.01-1.95, P = .042).

‖

Reference group.

View Large